Principal Scientist - Precision Medicine
Regeneron Pharmaceuticals
Summary
The Precision Medicine department at Regeneron is responsible for designing and executing the overarching translational and clinical biomarker strategies for therapeutic candidates during clinical development. We are seeking to hire a Precision Medicine Strategy Lead at the Principal Scientist level focusing on solid tumor oncology, heme malignancies, and immune oncology.
Job description
Principal Scientist, Precision Medicine (Biomarker) Strategy Lead
The Precision Medicine department at Regeneron is responsible for designing and executing the overarching translational and clinical biomarker strategies for therapeutic candidates during clinical development. We are seeking to hire a Precision Medicine Strategy Lead at the Principal Scientist level focusing on solid tumor oncology, heme malignancies, and immune oncology.
In this highly matrixed role, the Principal Scientist will be responsible for defining the key scientific questions relating to the drug target mechanism of action, disease biology and prognostic biomarkers associated with disease heterogeneity and severity, as well as informing potential patient stratification or selection. This information will guide development of a robust Precision Medicine strategy.
Discover your role:
- Leading focused assay development and implementation of assays and associated sample collections throughout a clinical trial.
- Coordinating data analysis through collaboration with computational scientists involved in integrating multi-omic data: genomics, transcriptomics, and proteomics.
- Interpreting results and leading communication of the key impact of the data to guide decision making to inform the clinical development strategy.
- Enabling advances in target identification, indication selection, early indication of biological activity and patient stratification/selection.
- Partnering cross-functionally across Research, Clinical Development, Clinical Pharmacology, Companion Diagnostics, Biostatistics, and Clinical Operations to ensure seamless scientific alignment.
- Managing internal and external research collaborations to enable development of clinical fit for purpose assays and translational research.
- Contributing to technical reports, study memos, clinical study reports, and scientific publications.
This role requires:
- The ability to drive, manage, execute and deliver timely results for complex scientific projects.
- Strong communication and presentation skills.
- A strategic understanding of the application of biomarker technologies to basic, translational or clinical research.
- Demonstrated ability to effectively collaborate and work in cross-functional teams.
- A Ph.D., M.D., or MS and 4-7 years' experience participating effectively on cross-disciplinary teams in pharmaceutical or biotech.
Requirements
- Ph.D., M.D., or MS degree
- 4-7 years' experience in pharmaceutical or biotech
- Ability to drive, manage, execute and deliver timely results for complex scientific projects
- Strong communication and presentation skills
- Strategic understanding of biomarker technologies in basic, translational or clinical research
- Demonstrated ability to effectively collaborate and work in cross-functional teams
Benefits
- Annual bonuses
- Incentive plans
- Equity awards
- Pension or retirement benefits
- 401(k) company match
- Health and wellness programs
- Fitness centers
- Insurance benefits
- Paid time off
- Family support benefits
Company overview
Regeneron Pharmaceuticals is a leading American biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company specializes in inventing, developing, and commercializing life-transforming medicines for people with serious diseases. Regeneron is renowned for its innovative antibody technologies and has developed several groundbreaking therapies, including EYLEA® for retinal diseases, DUPIXENT® for inflammatory conditions, and the COVID-19 antibody cocktail REGEN-COV®. The company operates with a strong focus on research and development across multiple therapeutic areas including ophthalmology, oncology, cardiovascular diseases, and rare genetic disorders. Regeneron's proprietary VelocImmune® technology platform enables the rapid generation of fully human monoclonal antibodies. With over 15,000 employees globally and annual revenues exceeding $14 billion, Regeneron has established itself as a major force in the biotechnology industry, consistently ranking among the top-performing pharmaceutical companies and maintaining a robust pipeline of investigational therapies.